Brought to you by 
LeukoSite, Ilex, and Schering sign Campath agreement
12 Nov 1999
Executive Summary
Ilex Oncology (drug development for cancer) and LeukoSite granted exclusive worldwide development and distribution rights, except in Japan and East Asia where they will retain rights, to Schering for Campath, a late-stage humanized monoclonal antibody that LeukoSite originally licensed from BTG PLC. Campath is used in the treatment of chronic lymphocytic leukemia (CLL), the most prevalent form of adult leukemia.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
LeukoSite, Ilex, and Schering sign Campath agreement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice